CDK inhibitor 4.35   Click here for help

GtoPdb Ligand ID: 10357

Synonyms: LGR4455
PDB Ligand
Compound class: Synthetic organic
Comment: Compound 4.35 is a selective inhibitor of CDKs 2, 5 and 9 [1]. It was designed for potential anti-lymphoma activity. Its cytotoxic effects on lymphoma cell lines are achieved via promotion of apoptosis. The co-crystal structure of 4.35 bound to CDK2/cyclin A2 has been submitted to the PBD with ID 6GVA [2] and this shows that the ligand binds to the kinase active site.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 130.7
Molecular weight 419.19
XLogP 3.52
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES NCCSc1nc(NCc2ccc(cc2)c2ccccn2)c2c(n1)c(n[nH]2)C(C)C
Isomeric SMILES NCCSc1nc(NCc2ccc(cc2)c2ccccn2)c2c(n1)c(n[nH]2)C(C)C
InChI InChI=1S/C22H25N7S/c1-14(2)18-19-20(29-28-18)21(27-22(26-19)30-12-10-23)25-13-15-6-8-16(9-7-15)17-5-3-4-11-24-17/h3-9,11,14H,10,12-13,23H2,1-2H3,(H,28,29)(H,25,26,27)
InChI Key PCQPAKMJSYGXRE-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
Bioactivity Comments
Compound 4.35 exhibits anti-tumour activity in vivo, in cell line xenograft and patient-derived xenograft mouse models [1]. Significant off-target activity was detected at CK1δ and CHK2, and weak inhibition of PAK4, CAMK1 and RSK1 kinases was measured.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
cyclin dependent kinase 1 Hs Inhibitor Inhibition 7.1 pKi - 1
⤷ pKi 7.1 (Ki 9x10-8 M) [1]
Description: Inhibition of CDK1/cyclin B1 complex.
cyclin dependent kinase 2 Hs Inhibitor Inhibition 8.2 – 8.7 pIC50 - 1
⤷ pIC50 8.7 (IC50 2x10-9 M) [1]
Description: Inhibition of CDK2/cyclin E1 complex.
pIC50 8.2 (IC50 6x10-9 M) [1]
Description: Inhibition of CDK2/cyclin A2 complex.
cyclin dependent kinase 5 Hs Inhibitor Inhibition 7.8 pIC50 - 1
⤷ pIC50 7.8 (IC50 1.5x10-8 M) [1]
Description: Inhibition of CDK5/cyclin p25 complex.
cyclin dependent kinase 9 Hs Inhibitor Inhibition 7.6 pIC50 - 1
⤷ pIC50 7.6 (IC50 2.5x10-8 M) [1]
Description: Inhibition of CDK9/cyclin T1 complex.
casein kinase 1 delta Hs Inhibitor Inhibition 7.3 pIC50 - 1
⤷ pIC50 7.3 (IC50 4.5x10-8 M) [1]
checkpoint kinase 2 Hs Inhibitor Inhibition 6.3 pIC50 - 1
⤷ pIC50 6.3 (IC50 5.25x10-7 M) [1]
cyclin dependent kinase 4 Hs Inhibitor Inhibition 6.2 pIC50 - 1
⤷ pIC50 6.2 (IC50 6.03x10-7 M) [1]
Description: Inhibition of CDK4/cyclin D1 complex.